What podcasts say about Novo Nordisk
Every statement, with the speaker, the exact quote and the moment it was said.
What experts have said about Novo Nordisk
43 statements · 22 positive · 18 negative · 1 mixed · 2 neutral
Novo Nordisk needs a stronger pipeline to advance its stock valuation.
“it's got to be pipeline oriented, I think, to get the stock to the next level.”
Open the episode · Market’s Post-Election Surge… And Prognosis For Pharma, Health Care After Midterms 11/4/26Listen at 33:35
- Hari RamachandraNegativeNov 1, 2026· The Investor's Podcast (We Study Billionaires) - The Investor’s Podcast Network
Novo Nordisk trades roughly 12 times forward earnings after falling 40% from its 52-week high.
“that stock is down 40%. And from its 52-week high, and it's trading roughly around 12 times forward earnings.”
Open the episode · TIP857: S&P Global, Novo, Deckers Brands w/ Stig Brodersen, Tobias Carlisle, & Hari RamachandraListen at 3:26
- Hari RamachandraPositiveNov 1, 2026· The Investor's Podcast (We Study Billionaires) - The Investor’s Podcast Network
Novo Nordisk is a century-old, high-quality business.
“it's a company that's 100 plus year old, great business.”
Open the episode · TIP857: S&P Global, Novo, Deckers Brands w/ Stig Brodersen, Tobias Carlisle, & Hari RamachandraListen at 4:12
- Hari RamachandraPositiveNov 1, 2026· The Investor's Podcast (We Study Billionaires) - The Investor’s Podcast Network
Novo Nordisk is a good business priced as if it were rapidly deteriorating.
“good business at a price that assumes that it's a melting ice cube”
Open the episode · TIP857: S&P Global, Novo, Deckers Brands w/ Stig Brodersen, Tobias Carlisle, & Hari RamachandraListen at 4:26
- Hari RamachandraPositiveNov 1, 2026· The Investor's Podcast (We Study Billionaires) - The Investor’s Podcast Network
Novo Nordisk can deliver mid-single-digit earnings growth and a 4.5% dividend without another blockbuster.
“my assumption is base case is even in a mediocre scenario, if they can't come up with another blockbuster, the earnings are in the mid single digits. And then we get a dividend of 4.5% to wait.”
Open the episode · TIP857: S&P Global, Novo, Deckers Brands w/ Stig Brodersen, Tobias Carlisle, & Hari RamachandraListen at 8:27
- Hari RamachandraPositiveNov 1, 2026· The Investor's Podcast (We Study Billionaires) - The Investor’s Podcast Network
Novo Nordisk could return 18% to 22% if its new drugs succeed.
“The returns can be in the upwards of 18% to 22%”
Open the episode · TIP857: S&P Global, Novo, Deckers Brands w/ Stig Brodersen, Tobias Carlisle, & Hari RamachandraListen at 11:37
- Hari RamachandraMixedNov 1, 2026· The Investor's Podcast (We Study Billionaires) - The Investor’s Podcast Network
Novo Nordisk could produce strong returns if Amicretin succeeds, otherwise returns may be 8–9%.
“I'm expecting really good returns if they're able to be successful with Omicretin. And that's the risk here. Else, you have to be satisfied with a mediocre return of 8% to 9%.”
Open the episode · TIP857: S&P Global, Novo, Deckers Brands w/ Stig Brodersen, Tobias Carlisle, & Hari RamachandraListen at 20:58
- Hari RamachandraPositiveNov 1, 2026· The Investor's Podcast (We Study Billionaires) - The Investor’s Podcast Network
Most negative news about Novo Nordisk is already reflected in its valuation.
“My thesis here is most of the bad news is baked in.”
Open the episode · TIP857: S&P Global, Novo, Deckers Brands w/ Stig Brodersen, Tobias Carlisle, & Hari RamachandraListen at 21:32
- Hari RamachandraPositiveNov 1, 2026· The Investor's Podcast (We Study Billionaires) - The Investor’s Podcast Network
Novo Nordisk’s valuation could improve if its pipeline produces successful drugs by 2028–2030.
“if they're able to get out with some good drugs, including Amicretin and others that they have by 28, 29, 30, then the valuation will also change accordingly.”
Open the episode · TIP857: S&P Global, Novo, Deckers Brands w/ Stig Brodersen, Tobias Carlisle, & Hari RamachandraListen at 22:01
Novo Nordisk retains long-term value despite current investor impatience.
“Looking over the longer term, I still believe that Novo has value”
Open the episode · Strong Dollar Keeps Climbing… And The Outlook For The Pharma Trade 10/5/26Listen at 32:33
Long-term holders of Novo Nordisk are likely to be rewarded.
“hold for a long time and likely you'll be rewarded”
Open the episode · Strong Dollar Keeps Climbing… And The Outlook For The Pharma Trade 10/5/26Listen at 33:28
The Nanexa deal is unlikely to trigger Novo Nordisk’s price in the short term.
“it's unlikely to be a short-term trigger for their price”
Open the episode · UBS Rises, Novo Climbs, HelloFresh PlummetsListen at 2:53
Novo Nordisk disappointed investors with its turnaround plans.
“Novo Nordisk. Disappointing investors here.”
Open the episode · Novo Slides; Accenture Up; Arhaus UpgradeListen at 2:22
Novo Nordisk quickly lost its GLP-1 market lead to Eli Lilly.
“it quickly lost its lead. to Eli Lilly.”
Open the episode · Novo Slides; Accenture Up; Arhaus UpgradeListen at 2:31
Novo Nordisk’s stock is approximately back to its pre-Wegovy level.
“If you look at Novo Nordistock, I think it's about where it was before Wiggovi came to the market”
Open the episode · A Breakthrough Cancer Vaccine Fueled a Biotech Rally. Can It Last?Listen at 18:50
Loss of exclusivity will challenge Novo Nordisk
“this loss of exclusivity on some of those drugs is going to be a huge challenge for Novo Nordisk”
Open the episode · Novo Nordisk Drops, Puma Down, Trainline RisesListen at 1:12
Novo Nordisk lost obesity-drug leadership to Eli Lilly
“They lost their leadership in the obesity drug race to Eli Lilly.”
Open the episode · Novo Nordisk Drops, Berkeley FallsListen at 1:14
Novo Nordisk’s weight-loss pill missed expectations
“The weight loss pill did not manage to beat expectations.”
Open the episode · Novo Nordisk Drops, Puma Down, Trainline RisesListen at 1:43
Novo Nordisk’s obesity and diabetes businesses are highly profitable.
“their obesity and diabetes businesses are now printing money.”
Open the episode · Mad Money w/ Jim Cramer 8/12/26Listen at 11:08
Novo Nordisk has 70% more U.S. product users than roughly one year earlier
“we have 70% more people in the U.S. using our products”
Open the episode · Mad Money w/ Jim Cramer 8/12/26Listen at 12:14
Novo Nordisk’s pill launch is the best pharmaceutical launch ever
“this makes this launch the best product launch in the history of pharmaceuticals.”
Open the episode · Mad Money w/ Jim Cramer 8/12/26Listen at 12:48
Sustained results could turn Novo Nordisk’s recent performance into a trend
“continue the results like we have shown in the last two quarters over a period of time, and then this moment turns into a trend”
Open the episode · Mad Money w/ Jim Cramer 8/12/26Listen at 20:35
Several factors may complicate Novo Nordisk’s outlook.
“there's going to be some, perhaps some things kind of complicating the outlook for Novo”
Open the episode · Novo Nordisk Drops, Next Jumps, Infineon FallsListen at 1:42
Novo Nordisk has experienced recent clinical-trial setbacks.
“there's been recent trial setbacks as well for Novo”
Open the episode · Novo Nordisk Drops, Next Jumps, Infineon FallsListen at 2:07
Novo Nordisk’s experimental drug failed to reduce cardiovascular risk in a large study.
“one of its experimental drugs failed to reduce the risk of heart disease and strokes in a large study”
Open the episode · Apple Tumbles, Amazon Soars, Novo Nordisk Slides as New Drug Fails in Closely Watched Heart, Stroke Study On this episode of Stock Movers:Listen at 3:01
Novo Nordisk needs a new growth source because its shares have lagged since 2024.
“the company really needs a new source of growth because shares have been lagging badly since that peak in 2024”
Open the episode · Apple Tumbles, Amazon Soars, Novo Nordisk Slides as New Drug Fails in Closely Watched Heart, Stroke Study On this episode of Stock Movers:Listen at 3:30
The failed drug study harms Novo Nordisk’s diversification effort beyond obesity and diabetes.
“This is a real blow for this company as it's trying to diversify away from obesity and the diabetes space where it's been the pioneer.”
Open the episode · Apple Slides Most Since 2025, Amazon Soars, NovoListen at 4:51
Novo Nordisk stock is reacting positively to the foundation initiative.
“Novo is, is reacting to that positively this morning.”
Open the episode · ASML Dips, Novo Jumps, Vestas GainsListen at 3:44
Novo Nordisk’s obesity-care unit is growing at its slowest rate since 2020.
“it's the slowest for that unit since 2020.”
Open the episode · SpaceX Agrees to Merge With Cursor; Novo to File for China Approval of Wegovy; Dave & Buster's Misses EstimatesListen at 2:55
Novo Nordisk is not performing well in its business.
“I don't want your own Nova Nordisk either, though. I think that they are not good at what they do.”
Open the episode · Mad Money w/ Jim Cramer 4/28/26Listen at 38:48
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.